Abstract
Seasonal respiratory viruses cause substantial pressure on healthcare systems, particularly over winter. System managers can mitigate the impact on patient care when they anticipate hospital admissions due to these viruses. Hospitalisation forecasts were used widely during the SARS-CoV-2 pandemic. Now, resurgent seasonal respiratory pathogens add complexity to system planning. We describe how a suite of forecasts for respiratory pathogens, embedded in national and regional decision-making structures, were used to mitigate the impact on hospital systems and patient care.
We developed forecasting models predicting hospital admissions and bed occupancy two weeks ahead for COVID-19, influenza, and RSV in England over winter 2023/24. Bed occupancy forecasts were informed by the ensemble admissions models. Forecasts were delivered in real-time at multiple scales. The use of sample-based forecasting allowed for effective reconciliation and trend interpretation.
Admission forecasts, particularly RSV and influenza, showed high skill at regional levels. Bed occupancy forecasts had well-calibrated coverage, owing to informative admissions forecasts and slower moving trends. National admissions forecasts had mean absolute percentage errors of 27.3%, 30.9% and 15.7% for COVID-19, influenza, and RSV respectively, with corresponding 90% coverages of 0.439, 0.807 and 0.779.
These real-time winter infectious disease forecasts produced by the UK Health Security Agency for healthcare system managers played an informative role in mitigating seasonal pressures. The models were delivered regularly and shared widely across the system to key users. This was achieved by producing reliable, fast, and epidemiologically informed ensembles of models. Though, a higher diversity of model approaches could have improved forecast accuracy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.